Innovations Proteomics Brings to Cancer Diagnosis and Treatment

Cancer is not only a genetic disease at the “cellular” level but also a proteomic disease. Disrupted protein structures impair important pathways and cause cancer. Proteomics studies proteins, more functionally active than genes, and offers hope for effective treatments and early diagnosis.
Recent proteomic research focuses on;
1. Discovering Rare Cancer Proteins: Failure to discover suitable biomarkers is the main reason for late diagnosis. Proteomics uses a system called mass spectrometry to identify proteins by analyzing mass. Research aims to detect cancer-causing proteins even in very small amounts. Traditional methods cannot identify these rare proteins at an early stage of disease.
Recent research seeks to detect HER2/neu in blood. Her2/neu is a growth factor particularly active in breast cancer. Drugs targeting it have been designed and are actively used. It is also highly active in 30 percent of breast, ovarian and pancreatic tumors. Usually, HER2/neu becomes detectable only after the tumor reaches a certain growth capacity. Using mass spectrometry, researchers successfully diagnosed cancer “at an early stage” in laboratory mice. Early-detected mouse cancers could be treated with targeted drugs, preventing visible tumor recurrence. Researchers aim to detect this protein from very small human blood samples in the near future.
2. Human Proteome Project: Mapping our entire genome took approximately 12 years. We have 22 thousand genes and 3 billion bases. Because proteins are more complex, mapping them will take longer. The human body has over 500.000 protein types. The proteome (all human proteins) has begun to be mapped. This project aims to reveal proteins' disease roles. Its cancer importance is discovering cancer-causing oncoproteins and enabling drug development.
3. Tumor Dormancy Research: As previously discussed, dormant cancer cells are a major cause of recurrence. How and when tumors become dormant remains unknown, but proteomics is advancing understanding. For example, certain proteins in blood platelets (thrombocytes) may provide information about dormant cancer cells.
In conclusion, proteomics has begun serving as a new “supporting” cancer research discipline. Soon it may clarify proteins' role in cancer and enable effective treatment design. Mass spectrometry may also determine “rapidly and in real time” whether biopsy tissue contains cancer cells.
Sources
2. Koomen, J. M., Haura, E. B., Bepler, G.
Proteomic Contributions to Personalized Cancer Care.
Molecular & Cellular Proteomics (2008) MCP, 7(10), 1780–1794.
3. Almog, N., & Klement, G. L.
Platelet Proteome and Tumor Dormancy: Can Platelets Content Serve as Predictive Biomarkers for Exit of Tumors from Dormancy?
Cancers, (2010). 2(2), 842–858.
Was this article helpful?
Your feedback helps us improve our content.





Reader comments
Share your comment
Your name and comment are published only after administrator approval. Your email address is never shown to visitors.
Be the first to comment.